prevention

Browse trials
Matrix  

Voglibosediabetes type 2, in all type of patients vs placebo

Diabetes by 54% suggested
Voglibosediabetes type 2, in people with impaired glucose tolerance vs placebo

Diabetes by 54% suggested
Vogliboseimpaired fasting glucose , in all type of patients vs placebo

Diabetes by 54% suggested
Candesartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo

all NS
Candesartanatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

all NS
Irbesartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo

hospitalisation for heart failure by 13% suggested
Irbesartan vs control

atrial fibrillation recurrence by 61% suggested
Valsartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo

all NS
Valsartanatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

atrial fibrillation by 33% suggested
Valsartandiabetes type 2, in all type of patients vs placebo

Diabetes by 10% suggested
Valsartandiabetes type 2, in people with impaired glucose tolerance vs placebo

Diabetes by 10% suggested
Valsartanimpaired fasting glucose , in all type of patients vs placebo

Diabetes by 10% suggested
Orlistatdiabetes type 2, in all type of patients vs placebo

Diabetes by 57% suggested
Orlistatdiabetes type 2, in people with impaired glucose tolerance vs placebo

Diabetes by 57% suggested
Glipizidediabetes type 2, in all type of patients vs placebo

all NS
Glipizidediabetes type 2, in people with impaired glucose tolerance vs placebo

all NS
Metformindiabetes type 2, in all type of patients vs control

all NS
Metformin vs placebo

Diabetes by 33% suggested
Metformindiabetes type 2, in people with impaired glucose tolerance vs control

all NS
Metformin vs placebo

Diabetes by 50% suggested
Metforminimpaired fasting glucose , in all type of patients vs placebo

Diabetes by 50% suggested
Nateglinidediabetes type 2, in all type of patients vs placebo

all NS
Nateglinidediabetes type 2, in people with impaired glucose tolerance vs placebo

all NS
Nateglinideimpaired fasting glucose , in all type of patients vs placebo

all NS
Rosiglitazonediabetes type 2, in all type of patients vs placebo

normoglycemia by 110% suggested

cardiovascular events by 52% suggested

Diabetes by 53% suggested
Rosiglitazonediabetes type 2, in people with impaired glucose tolerance vs placebo

normoglycemia by 110% suggested

cardiovascular events by 52% suggested

Diabetes by 53% suggested
Rosiglitazoneimpaired fasting glucose , in all type of patients vs placebo

normoglycemia by 110% suggested

cardiovascular events by 52% suggested

Diabetes by 53% suggested
Troglitazonediabetes type 2, in all type of patients vs placebo

all NS
Troglitazonediabetes type 2, in people with impaired glucose tolerance vs placebo

all NS
Enalaprilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

atrial fibrillation by 78% suggested
Enalaprilatrial fibrillation, in patient with history of atrial fibrillation vs control

all NS
Lisinoprilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

all NS
Lisinoprilatrial fibrillation, in patient with history of atrial fibrillation vs placebo

all NS
Ramiprildiabetes type 2, in all type of patients vs placebo

all NS
Ramiprildiabetes type 2, in people with impaired glucose tolerance vs placebo

all NS
Ramiprilimpaired fasting glucose , in all type of patients vs placebo

all NS
Gemfibrozilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

all NS
Losartanatrial fibrillation, in patients without history of AF (primary prevention) vs atenolol

atrial fibrillation by 34% suggested
Glarginediabetes type 2, in all type of patients vs placebo

all NS
Glarginediabetes type 2, in people with impaired glucose tolerance vs placebo

all NS
Glargineimpaired fasting glucose , in all type of patients vs placebo

all NS
Dietdiabetes type 2, in all type of patients vs AHA 1 diet

all NS
Dietdiabetes type 2, in people with impaired glucose tolerance vs AHA 1 diet

all NS
Folic acidpost stroke, in patients with prior stroke or TIA vs placebo

all NS
Folic acid vs low dose - folic acid, vit B12 and vit B6

all NS
Atorvastatinatrial fibrillation, in patient with history of atrial fibrillation vs control

all NS
Atorvastatin vs placebo

atrial fibrillation recurrence by 36% suggested
Atorvastatinatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

all NS
Pravastatinatrial fibrillation, in patient with history of atrial fibrillation vs control

all NS
Rosuvastatinatrial fibrillation, in patients without history of AF (primary prevention) vs placebo

all NS

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons